Maravai Lifesciences Holdings Inc (MRVI)
Drugs • Health Care
July 22, 2026 Maravai LifeSciences Prepares for Second Quarter Earnings Announcement Maravai LifeSciences will announce its Q2 earnings on August 6, 2026, followed by a conference call for stakeholders. The company is recognized for its essential life science services and is well-positioned in the evolving biotech industry.
July 20, 2026 Maravai Lifesciences Strengthens Global IP Position with New Patent for CleanCap Technology Maravai Lifesciences, through TriLink BioTechnologies, has secured a new patent for its CleanCap technology, improving mRNA production methods. This patent strengthens its intellectual property globally, especially in China, and supports the growth of mRNA-based therapies.
June 16, 2026 Maravai LifeSciences Expands Capabilities with New GMP Enzyme Manufacturing Facility Maravai LifeSciences has launched TriLink BioTechnologies' new GMP enzyme manufacturing facility in Florida, addressing sourcing challenges for RNA therapeutics. This state-of-the-art facility simplifies supply chains and enhances efficiency with their flagship GMP CleanScribe™ RNA Polymerase, reducing double-stranded RNA formation significantly.
June 03, 2026 Maravai LifeSciences Announces Strategic Refinancing to Strengthen Financial Position Maravai LifeSciences has entered a new $150 million term loan and $30 million revolving credit facility to reduce long-term debt and enhance liquidity. This refinancing is a strategic move to support growth in drug therapies and vaccines, positioning the company for future success in the life sciences sector.
May 08, 2026 Maravai Lifesciences Holdings Inc. Reports Strong Q1 Results for 2026 Amid Strategic Realignment Maravai Lifesciences reported a significant revenue increase to $65.8 million in Q1 2026, driven by its TriLink segment. Despite a net loss, strategic cost management positions the company for future growth in the life sciences sector.
April 20, 2026 Maravai LifeSciences Announces Upcoming Earnings Conference Call Maravai LifeSciences will announce its Q1 2026 financial results on May 7, 2026, during a conference call and webcast. Stakeholders will gain insights into the company's performance and future strategies in the evolving life sciences industry.
February 26, 2026 Maravai Lifesciences Holdings Inc. 2025 Annual Report: Navigating Challenges and Charting a Path Forward Maravai Lifesciences Holdings Inc. faced significant challenges in 2025, reporting a revenue decline and restructuring initiatives. The company aims to enhance growth through acquisitions and strategic realignment while addressing financial strains and legal proceedings.
February 25, 2026 Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results Maravai LifeSciences reported a net loss of $230.8 million for 2025 but achieved positive Adjusted EBITDA in Q4. The company projects revenue growth for 2026, aiming for $200-$210 million.
February 09, 2026 Maravai LifeSciences Set to Reveal Financial Results on February 25, 2026 Maravai LifeSciences will announce its Q4 and full year 2025 financial results on February 25, 2026. A conference call will follow to provide insights into the company's performance and future strategies.
November 10, 2025 Maravai LifeSciences Sets November Investor Conference Schedule Maravai LifeSciences will participate in two major investor conferences in November 2025, featuring CFO Raj Asarpota. The events will provide insights into the company's growth and strategies in the life sciences sector, with webcasts available for broader engagement.
November 07, 2025 Maravai Lifesciences Holdings Inc. Reports Q3 2025 Results: Navigating Challenges Amid Strategic Shifts Maravai Lifesciences Holdings Inc. reported a 39.7% decline in Q3 2025 revenues, driven by reduced CleanCap demand. Despite challenges, strategic acquisitions and leadership changes aim to navigate the company towards recovery.
November 06, 2025 Maravai LifeSciences Reports Third Quarter 2025 Financial Results Maravai LifeSciences experienced a challenging third quarter in 2025, reporting a 39.7% revenue decline. Despite the downturn, leadership remains optimistic about future growth, particularly in the TriLink segment.
October 22, 2025 Maravai LifeSciences Prepares for Q3 Earnings Call: Key Insights and Expectations Maravai LifeSciences will announce its Q3 2025 earnings on November 6, followed by a conference call at 2 PM PT. The call aims to provide insights into the company's financial health and future strategies in the evolving life sciences sector.
August 11, 2025 Maravai Lifesciences Holdings Inc. Reports Q2 2025 Results Amid Strategic Shifts Maravai Lifesciences Holdings Inc. reported a 31.7% decline in Q2 2025 revenues, driven by challenges in the Nucleic Acid Production segment. The company is undertaking strategic acquisitions and a corporate realignment to drive future growth despite ongoing market difficulties.
May 14, 2025 Maravai Lifesciences Partners with IVI to Advance mRNA Vaccine Development Maravai Lifesciences and the International Vaccine Institute have formed a partnership to advance mRNA vaccine development, focusing on enhancing access in low- and middle-income countries. This collaboration aims to leverage TriLink's innovative technology and IVI's global reach to address health disparities and ensure equitable vaccine distribution.
May 12, 2025 Maravai Lifesciences Holdings Inc. Reports Challenging Q1 2025 Results Maravai Lifesciences Holdings Inc. reported a significant revenue decline in Q1 2025, largely due to decreased demand for CleanCap products. Despite strategic acquisitions aimed at innovation, the company faces a challenging financial outlook with increased losses and market uncertainties.
May 05, 2025 Maravai Lifesciences Faces Legal Scrutiny Amid Revenue Recognition Issues Maravai Lifesciences is under investigation due to allegations of misleading financial practices, including premature revenue recognition and inadequate internal controls. A federal class action lawsuit has been filed, with a deadline for affected investors to take action by May 5, 2025. Stakeholders are closely monitoring the situation as it unfolds.
April 27, 2025 Maravai Lifesciences Holdings Faces Class Action Lawsuit Amid Allegations of Misleading Financial Reports Maravai Lifesciences is facing a class action lawsuit from shareholders alleging misleading financial statements and inadequate internal controls. The lawsuit highlights serious concerns about the company's revenue recognition practices and overstated goodwill. Shareholders are encouraged to act promptly if they wish to participate.
April 17, 2025 Maravai Lifesciences Faces Legal Challenges Following Revenue Recognition Missteps Maravai Lifesciences is embroiled in a class action lawsuit due to revenue recognition errors that led to a significant stock decline. Investors are urged to stay informed as the company navigates these legal challenges and assesses its financial practices.
March 18, 2025 Maravai Lifesciences Holdings Inc. Reports 2024 Annual Results: A Year of Challenges and Strategic Moves Maravai Lifesciences reported a 10.3% decline in revenue for 2024, totaling $259.2 million, primarily due to reduced demand in Nucleic Acid Production. Despite significant losses, the company is pursuing strategic acquisitions and innovation to recover and strengthen its market position.
March 18, 2025 Maravai Lifesciences Reports Financial Results for Q4 and Full Year 2024 Maravai Lifesciences reported a 23.7% revenue decline in Q4 2024, yet improved its net loss. The company is focused on strategic acquisitions and leadership changes to enhance growth prospects.
March 10, 2025 Maravai Lifesciences Holdings Inc Faces Class Action Lawsuit Over Alleged Securities Violations Maravai Lifesciences Holdings Inc. is facing a class action lawsuit filed by Bronstein, Gewirtz & Grossman LLC over alleged securities violations. Investors claim the company made misleading statements about its financial health, particularly regarding revenue recognition and internal controls. The lawsuit invites affected investors to participate by May 5, 2025.
March 10, 2025 Maravai Lifesciences Faces Class Action Lawsuit Following Revenue Recognition Issues Maravai Lifesciences is facing a class action lawsuit following significant revenue recognition errors that led to a sharp decline in its stock price. The lawsuit alleges misleading statements and inadequate internal controls. Affected investors need to act by May 4, 2025.
March 07, 2025 Maravai LifeSciences Faces Legal Challenge Amid Revenue Recognition Issues Maravai LifeSciences is facing a securities fraud lawsuit after announcing a $3.9 million revenue recognition error and a significant decline in stock price. Investors are encouraged to participate in the class action lawsuit before the May 5, 2025 deadline to protect their interests.
March 06, 2025 Maravai LifeSciences Faces Class Action Lawsuit Following Revenue Recognition Errors Maravai LifeSciences is facing a class action lawsuit due to significant revenue recognition errors that have harmed investors. The lawsuit highlights inadequate internal controls and misleading statements by the company, prompting affected investors to act before the May 5, 2025 deadline.
March 05, 2025 Maravai Lifesciences Faces Class Action Lawsuit Following Earnings Report Delay Maravai Lifesciences is under a class action lawsuit due to a revenue recognition error that impacted its earnings. The company's stock fell 21% after the announcement, highlighting concerns over its financial reporting practices. Investors have until May 5, 2025, to seek lead plaintiff status.
March 05, 2025 Maravai LifeSciences Faces Legal Challenges Following Revenue Recognition Issues Maravai LifeSciences is facing a class action lawsuit following a revenue recognition error that led to a significant stock price drop. The lawsuit alleges misleading financial statements and inadequate internal controls, impacting investors who purchased shares during the specified timeframe.
March 04, 2025 Maravai Lifesciences Faces Class Action Lawsuit Following Revenue Recognition Errors Maravai Lifesciences is facing a class action lawsuit alleging securities fraud due to revenue recognition errors and inadequate internal controls. The lawsuit has led to a significant drop in stock prices, prompting affected investors to take action.
March 04, 2025 Maravai Lifesciences Faces Legal Scrutiny Over Financial Reporting Issues Maravai Lifesciences is facing an investigation over allegations of misleading financial statements and inadequate internal controls. Key issues include inaccurate revenue recognition and overstated goodwill, impacting investor confidence and stock performance. The deadline for investors to seek lead plaintiff status is May 5, 2025.
March 04, 2025 Maravai Lifesciences Faces Securities Fraud Lawsuit: A Closer Look at the Allegations Maravai Lifesciences is under scrutiny due to a class action lawsuit alleging securities fraud and misleading financial statements from August 2024 to February 2025. Affected investors are encouraged to join the lawsuit before the May 5, 2025 deadline to recover potential losses.
February 26, 2025 Maravai Lifesciences Under Investigation Amid Earnings Release Delay Maravai Lifesciences is under investigation after delaying its earnings release due to potential impairment charges and an accounting error. The company's stock has suffered a significant drop, leading to concerns about its financial integrity and prompting legal action from investors seeking recovery.
February 25, 2025 Maravai LifeSciences' Earnings Delay Sends Shares Tumbling Amid Fraud Investigation Maravai LifeSciences' shares plummeted over 21% following the delay of its 2024 earnings report, raising concerns over internal financial controls. The company is facing scrutiny over a potential impairment charge and revenue recognition errors, prompting an investigation by Gibbs Law Group into possible securities law violations.
February 25, 2025 Maravai LifeSciences Faces Scrutiny Amid Financial Reporting Delays Maravai LifeSciences has delayed its earnings report due to concerns over a potential impairment charge and a revenue recognition error. This has led to a significant drop in stock prices and an investigation by legal representatives on behalf of affected investors.
February 25, 2025 Maravai LifeSciences Postpones Earnings Release for 2024 Maravai LifeSciences has postponed its 2024 earnings release to assess goodwill impairment and rectify a revenue recognition error. The company will file necessary documents by March 18, 2025, while ensuring revenue projections remain on track.
February 25, 2025 Maravai Lifesciences Holdings Inc Faces Securities Fraud Investigation Amid Earnings Release Delay Maravai Lifesciences is under investigation for potential securities fraud following a delay in its earnings release, linked to accounting errors. The company's stock suffered a significant drop, raising concerns among investors about financial transparency and reporting practices. Legal actions may follow as investors seek to recover losses.
February 24, 2025 Maravai LifeSciences Completes Strategic Acquisition of Officinae Bio's DNA and RNA Business Maravai LifeSciences has completed the acquisition of Officinae Bio's DNA and RNA business, enhancing its mRNA and CRISPR technology capabilities. This strategic move aims to expedite drug development processes and expand Maravai's presence in the European market.
February 18, 2025 SWOT Analysis of Maravai Lifesciences Holdings Inc. in 2025 This SWOT analysis of Maravai Lifesciences Holdings Inc. in 2025 delves into the company's strengths in nucleic acid production, weaknesses related to customer dependency, and growth opportunities in emerging markets. It also addresses threats from competition and regulatory changes, providing a comprehensive view of the company's strategic position.
November 12, 2024 Maravai Lifesciences Holdings Inc. Reports Q3 2024 Financial Results Maravai Lifesciences reported mixed Q3 2024 financial results, with revenues declining to $65.2 million and a substantial goodwill impairment of $154.2 million. Despite challenges, the company maintains strong liquidity and is focused on strategic growth through acquisitions and infrastructure investments.
August 08, 2024 Maravai Lifesciences Holdings Inc. Reports Mixed Results in Q2 2024 Maravai Lifesciences reported mixed Q2 2024 results with a 6.5% revenue increase year-over-year, driven by nucleic acid production. However, rising operational costs and a decline in net income pose challenges for future growth.
May 09, 2024 Maravai Lifesciences Holdings Inc. Reports Q1 2024 Financial Results: A Mixed Bag Amidst Strategic Realignment Maravai Lifesciences' Q1 2024 financial results reveal a revenue drop to $64.2 million, influenced by challenges in the Nucleic Acid Production segment. Despite a net loss of $12.07 million, the Biologics Safety Testing segment showed growth, prompting management's focus on restructuring for future recovery.